Positiv
●
Seeking Alpha
●
vor 5 Monaten
Krystal Biotech is upgraded to Strong Buy, driven by Vyjuvek's commercial success and a robust catalyst-rich pipeline. KRYS boasts 96% gross margins, nearly $1B in cash, and a platform poised to deliver four rare disease drugs by 2030. Recent positive Phase 1 data for KB407 in cystic fibrosis derisks inhaled delivery, enhancing confidence in upcoming AATD and NSCLC programs.